Related Experiment Video
Updated: May 4, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis
Guoping Zhao1, Yanglong Zhu, Colins O Eno
1Molecular Targets Program, James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA.
Abstract:
The proapoptotic Bcl-2 protein Bax by itself is sufficient to initiate apoptosis in almost all apoptotic paradigms. Thus, compounds that can facilitate disruptive Bax insertion into mitochondrial membranes have potential as cancer therapeutics. In our study, we have identified small-molecule compounds predicted to associate with the Bax hydrophobic groove by a virtual-screen approach. Among these, one lead compound (compound 106) promotes Bax-dependent but not Bak-dependent apoptosis. Importantly, this compound alters Bax protein stability in vitro and promotes the insertion of Bax into mitochondria, leading to Bax-dependent permeabilization of the mitochondrial outer membrane. Furthermore, as a single agent, compound 106 inhibits the growth of transplanted tumors, probably by inducing apoptosis in tumors. Our study has revealed a compound that activates Bax and induces Bax-dependent apoptosis, which may lead to the development of new therapeutic agents for cancer.
Insights
Researchers discovered a novel compound that activates the proapoptotic protein Bax, initiating cancer cell death. This Bax-activation may lead to new cancer therapeutics by targeting tumor apoptosis.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Therapeutics
Background:
- The proapoptotic protein Bax is crucial for initiating apoptosis.
- Compounds facilitating Bax insertion into mitochondrial membranes are potential cancer therapeutics.
Purpose of the Study:
- Identify small-molecule compounds that associate with the Bax hydrophobic groove.
- Evaluate a lead compound's ability to induce Bax-dependent apoptosis and inhibit tumor growth.
Main Methods:
- Virtual screening to identify potential Bax-associating compounds.
- In vitro assays to assess compound effects on Bax stability and mitochondrial insertion.
- In vivo studies using transplanted tumors to evaluate therapeutic potential.
Main Results:
- One lead compound (compound 106) was identified, promoting Bax-dependent apoptosis.
- Compound 106 alters Bax protein stability and facilitates its insertion into mitochondria.
- Compound 106 inhibits transplanted tumor growth as a single agent, likely via tumor apoptosis.
Conclusions:
- A novel compound activates Bax and induces Bax-dependent apoptosis.
- This compound demonstrates potential as a new therapeutic agent for cancer treatment.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Apoptosis
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Cellular Injury V: Apoptosis and Autophagy
Caspases

